Animal and Translational Models for CNS Drug Discovery: Reward Deficit Disorders

"Reward Deficit Disorders" is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for reward deficit disorders such as alcohol dependence, nicotine dependence, heroin and cocaine addiction, obesity, and gambling and impulse control disorders. "Reward Deficit Disorders" has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of: academic basic neuroscientific research, applied pharmaceutical drug discovery and development, and issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. "Reward Deficit Disorders" also has a section dedicated to the specifics of the regulatory aspects to abuse liability testing. The aim of this series of volumes on "Animal and Translational Models for CNS Drug Discovery" is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the third volume in the three volume-set, "Animal and Translational Models for CNS Drug Discovery" (9780123738615), which is also available for purchase individually. It provides clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery process. It offers critical evaluation of animal and translational models improving transition from drug discovery and clinical development. It emphasizes what results mean to the overall drug discovery process. It explores issues in clinical trial design and conductance in each therapeutic area. "Neurological Disorders" is available for purchase individually.